Read: A startup cofounded by a 30-year-old just got $38 million to revolutionize the way we transplant organs (Business Insider, 3/16/17)
eGenesis is a life sciences company focused on leveraging gene editing technology to deliver safe and effective human transplantable cells, tissues and organs to the hundreds of thousands of patients worldwide who are in dire need.
300 Technology Square, Suite 301
Cambridge, MA 02139
- eGenesis Appoints Industry Veteran Paul Sekhri as President and Chief Executive Officer
- Julie Sunderland, CEO at eGenesis, explains a gene editing platform for the development of human-compatible organs, tissues and cells
- eGenesis Appoints William Westlin, Ph.D., as Executive Vice President of Research & Development